Safety and Immunogenicity Study of IP-QSV Vaccine in Healthy Adults/Adolescents, Children and Infants

NCT07666750 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

370

Enrollment

OTHER

Sponsor class

Conditions

Shigella Infection

Interventions

BIOLOGICAL: 30μg IP-QSV
OTHER: Placebo
BIOLOGICAL: 10μg IP-QSV
BIOLOGICAL: 2μg IP-QSV

Sponsor

International Vaccine Institute

Collaborators

[object Object]